Politician trade (House)

AbbVie (ABBV): Rep. Josh Gottheimer (NJ05) disclosed a partial sale $1K–$15K

Rep. Josh Gottheimer (NJ05) disclosed a partial sale of AbbVie in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
21 days
Disclosure lag
Traded
Jan 27, 2023
Disclosed
Feb 17, 2023

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 20, 2023CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
  2. Jan 27, 2023 · this disclosureCongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000

What came next

  1. Jan 31, 2023CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  2. Feb 7, 2023CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
  3. Feb 21, 2023CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
  4. Mar 6, 2023CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  5. Mar 7, 2023CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  6. Mar 24, 2023CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
  7. Apr 3, 2023CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
  8. Apr 10, 2023CongressDisclosed partial sale of ABBV — reported range $15,001 - $50,000
  9. Apr 28, 2023Congress · 1 personMembers of Congress: 3 sales
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for AbbVie

For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

Other recent filings by Rep. Josh Gottheimer (NJ05)

The full history of Rep. Josh Gottheimer (NJ05) is on the profile page.

How this filing works

Explore the data

Common questions

Which member of Congress traded AbbVie (ABBV) stock, and how much?

Rep. Josh Gottheimer (NJ05) disclosed a partial sale of AbbVie in the $1K–$15K range. Reported range, not an exact amount, Joint account.

When did it happen, and when was it made public?

Traded: Jan 27, 2023. Disclosed: Feb 17, 2023. That is 21 days between the two dates.

Why is the amount a range and not an exact figure?

Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.

Where does this information come from?

From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about AbbVie recently?

For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABBV page.

Does this mean ABBV stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at AbbVie

Everything OQRO holds on this company is on its ABBV page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data